Literature DB >> 7883781

Characterization of chemotherapy-induced morphonuclear modifications in the P388 leukaemia and the MXT mammary tumour models of the mouse.

V Budel1, O Pauwels, J Francisco, P Gasperin, J L Pasteels, R Kiss.   

Abstract

Chemotherapy-induced morphonuclear modifications were monitored in vivo by means of the digital cell image analysis of Feulgen-stained nuclei. Two experimental models were used, i.e. the P388 mouse leukaemia and the MXT mouse mammary carcinoma. The drugs used were doxorubicin, etoposide and cyclophosphamide. The results indicate that the chemotherapy induced a significant decrease in the MXT tumour growth and a significant increase in the survival of the P388 leukaemic mice. These effects were accompanied at the morphonuclear level by an increase in the nuclear area, by modifications in the DNA content in accordance with the effects of the drugs on the cell cycle and by several modifications in the chromatin texture in accordance with the model or the drugs studied. While there were neither homogeneous morphonuclear changes in all treatment groups nor clearcut correlations between the morphonuclear changes and tumour growth or the survival of the animals, the present study nevertheless shows that it is possible, at least partly, to monitor in vivo certain chemotherapy-induced effects occurring at the morphonuclear level, and subsequently to obtain information on the mode of action of the drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7883781     DOI: 10.1007/bf01202219

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  26 in total

1.  The effect of adriamycin on the cell cycle traverse of a human lymphoid cell line.

Authors:  B Barlogie; B Drewinko; D A Johnston; E J Freireich
Journal:  Cancer Res       Date:  1976-06       Impact factor: 12.701

2.  Estrogen receptor characterization in a transplantable mouse mammary tumor.

Authors:  C Watson; D Medina; J H Clark
Journal:  Cancer Res       Date:  1977-09       Impact factor: 12.701

Review 3.  Antineoplastic drugs in 1990. A review (Part I).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-04       Impact factor: 9.546

4.  Influence of pituitary grafts or prolactin administrations on the hormone sensitivity of ovarian hormone-independent mouse mammary MXT tumors.

Authors:  R Kiss; Y de Launoit; A Danguy; R Paridaens; J L Pasteels
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

5.  Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide.

Authors:  B H Long; S T Musial; M G Brattain
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

6.  Numerical evaluation of cytologic data. V. Bivariate distributions and the Bayesian decision Boundary.

Authors:  P H Bartels
Journal:  Anal Quant Cytol       Date:  1980-06

7.  An improved method for analyzing survival data from combination chemotherapy experiments.

Authors:  W H Carter; D M Stablein; G L Wampler
Journal:  Cancer Res       Date:  1979-09       Impact factor: 12.701

8.  Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.

Authors:  A Pierré; L Kraus-Berthier; G Atassi; S Cros; M F Poupon; G Lavielle; M Berlion; J P Bizzari
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

Review 9.  Considerations in the design of possible cell cycle effective drugs.

Authors:  F Mauro; W Göhde; J Schumann; L Teodori; M Spanò
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1986-02

10.  In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.

Authors:  S Binet; A Fellous; H Lataste; A Krikorian; J P Couzinier; V Meininger
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

View more
  1 in total

Review 1.  Testing electromagnetic fields for potential carcinogenic activity: a critical review of animal models.

Authors:  J McCann; R Kavet; C N Rafferty
Journal:  Environ Health Perspect       Date:  1997-02       Impact factor: 9.031

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.